GlassScriptPhysician profile
Ronald P Tynes
NPI 1033450333
$2,503.80
in general payments reported to CMS, 2019-2025
21 companies · $424 in 2025
The $424 reported for 2025 was more than what a typical Acute Care (Nurse Practitioner) provider received nationally (typical 2025 total: $151).
See the full distribution for Acute Care (Nurse Practitioner)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $222 · 2022: $517 · 2023: $791 · 2024: $550 · 2025: $424.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,765.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,765.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $769.65 | 2021-2025 | |
| Merck Sharp & Dohme LLC | $411.51 | 2022-2025 | Verquvo |
| Janssen Pharmaceuticals, INC | $194.05 | 2021-2024 | Xarelto |
| Abbott Laboratories | $161.61 | 2021-2025 | Confirm Rx |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $145.11 | 2021-2025 | Lifevest |
| Amgen INC. | $102.78 | 2021-2023 | Repatha |
| Baxter Healthcare | $94.27 | 2023-2024 | Hillrom - Carnation Ambulatory Monitor |
| Inspire Medical Systems, INC. | $88.86 | 2023-2025 | Inspire |
| Boehringer Ingelheim Pharmaceuticals, INC. | $79.26 | 2023-2024 | Jardiance |
| Bayer Healthcare Pharmaceuticals INC. | $79.03 | 2025 | |
| Pfizer INC. | $73.95 | 2021-2025 | |
| E.R. Squibb & Sons, L.L.C. | $70.95 | 2022-2024 | Camzyos, Eliquis |
| Lexicon Pharmaceuticals, INC. | $52.76 | 2023-2024 | Inpefa |
| Sanofi-Aventis U.S. LLC | $45.00 | 2023 | |
| Medtronic, INC. | $28.30 | 2023 | Micra |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $20.51 | 2024 | Injectafer |
| Scpharmaceuticals INC. | $20.03 | 2025 | |
| Kestra Medical Technology Services, INC. | $18.31 | 2025 | Assure Wcd |
| Esperion Therapeutics, INC. | $17.47 | 2021 | |
| Novo Nordisk INC | $17.04 | 2025 | Wegovy |
| Astrazeneca Pharmaceuticals LP | $13.35 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Tynes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.